Drug intelligence / Profile preview

alpha linolenic acid + diindolylmethane + lauric acid

Development stage: Preclinical
Lead developer: Icahn School of Medicine
Modality: Small Molecules
Administration: Oral

Overview

A combination of three compounds (alpha linolenic acid, diindolylmethane, and lauric acid) formulated for targeted colonic delivery to activate nutrient sensing receptors GPR84 and FFAR4 (GPR120). This combination has been shown to reduce caloric intake in obese individuals by promoting satiety through stimulation of gut hormone release.

Targets

FFAR4 (Free fatty acid receptor 4)GPR84

Beyond the preview

Go deeper on alpha linolenic acid + diindolylmethane + lauric acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on alpha linolenic acid + diindolylmethane + lauric acid.

Explore the full profile